Alessandra Ferrajoli

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 23 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood(2025)10.1182/blood.2024024476

N/A

0.710DataRank · unranked

42 citations

Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn +22 more

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

Leukemia & Lymphoma(2008)10.1080/10428190701882146

N/A

0.697DataRank · unranked

103 citations

Samih El Ahdab, Farhad Ravandi, Stefan Faderl, Alessandra Ferrajoli, Beth Newman +3 more

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32623

N/A

0.464DataRank · unranked

21 citations

Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva +11 more

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia

Annals of Oncology(2023)10.1016/j.annonc.2023.06.007

N/A

0.396DataRank · unranked

13 citations

Joshua W.D. Tobin, Yongwoo David Seo, Georgina Gener‐Ricos, Emily Z. Keung, Elizabeth M. Burton +28 more

Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia

Leukemia & Lymphoma(2024)10.1080/10428194.2024.2349700

N/A

0.373DataRank · unranked

11 citations

Wei‐Ying Jen, Hagop M. Kantarjian, David McCue, Fadi G. Haddad, William Wierda +10 more

Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study

Journal of Cancer Survivorship(2025)10.1007/s11764-024-01555-w

N/A

0.345DataRank · unranked

9 citations

Max J. Gordon, Melissa M. Markofski, Emily C. LaVoy, Susan K. Peterson, Liang Li +7 more

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression

Blood Cancer Journal(2025)10.1038/s41408-025-01382-x

N/A

0.165DataRank · unranked

2 citations

Burcu Aslan, Ganiraju C. Manyam, LaKesla R. Iles, Natalia Timofeeva, Neetu Singh +8 more

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

American Journal of Hematology(2022)10.1002/ajh.26595

N/A

0DataRank · unranked

14 citations

Raamis Khwaja, Rashmi Kanagal‐Shamanna, Guilin Tang, Jan A. Burger, Philip A. Thompson +10 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood(2023)10.1182/blood-2023-190712

N/A

0DataRank · unranked

1 citations

David Harris, Uri Rozovski, Ping Li, Zhiming Liu, Taghi Manshouri +15 more

Decreased Transfusions in Premenopausal Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation Given Leuprolide According to an Abnormal Uterine Bleeding Algorithm

JCO Oncology Practice(2024)10.1200/op.24.00169

N/A

0DataRank · unranked

2 citations

Lee Cheng, Amin M. Alousi, Alessandra Ferrajoli, Denise Nebgen

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Cancer(2021)10.1002/cncr.33409

N/A

0DataRank · unranked

10 citations

Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour +16 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Blood(2020)10.1182/blood.2020006322

N/A

0DataRank · unranked

36 citations

Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp, Fatima Abbasi +23 more

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32627

N/A

0DataRank · unranked

34 citations

Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi +14 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma

Leukemia(2021)10.1038/s41375-021-01181-w

N/A

0DataRank · unranked

29 citations

Christopher P. Mill, Dimuthu Perera, Christine Birdwell, Qing Deng, Haopeng Yang +13 more

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Blood(2021)10.1182/blood.2021012315

N/A

0DataRank · unranked

24 citations

Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson +4 more

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells

Oncotarget(2021)10.18632/oncotarget.27884

N/A

0DataRank · unranked

11 citations

David Harris, Ping Li, Zhiming Liu, Preetesh Jain, Taghi Manshouri +10 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more